Biomea Fusion is trading 6.18% down at $1.59 as dilution and financing concerns persist after it terminated its proposed offering.
- On September 22, 2026, the company announced an underwritten offering of common stock and pre-funded warrants.
- On September 23, 2026, it terminated the proposed offering, saying market conditions were not conducive to acceptable terms; no securities were sold.
- The stock remains under pressure while the broader biotech sector is higher.